Prognostic scoring systems based on physiological parameters have been established in order to predict the outcome of ICU patients. It has been demonstrated that the predictive value of these scores is limited in patients following hematopoietic stem cell transplantation (HSCT). Therefore, we evaluated patients from the Dü sseldorf pediatric stem cell transplantation center with regard to predisposing factors and prognostic variables for ICU treatment and outcome. Between January 1989 and December 1998, 180 HSCT have been performed. The clinical, laboratory and HSCT-related parameters such as conditioning treatment, engraftment, GVHD, infections and HSCT toxicity were prospectively recorded and retrospectively analyzed. Established pediatric scoring systems (PRISM, TISS, P-TISS) were applied. Twenty-eight patients required intensive care (16 male, 12 female, median age: 10.9 years (range: 0.4 to 18.9 years), five autologous, 13 allogeneic-related and 10 unrelated transplanted patients). Ventilator-dependent respiratory failure was the most frequent cause of admission to the ICU (n ‫؍‬ 23). Fourteen of 28 patients were discharged from ICU, and six of 28 patients achieved a long-term survival (110 to 396 weeks). At admission to the ICU, impaired cardiovascular status, high CRP levels and presence of macroscopic bleeding were each associated with fatal outcome (P Ͻ 0.05). The Pediatric Risk of Mortality (PRISM) score was not prognostically significant at the 0. 
Hematopoietic stem cell transplantation (HSCT) is associated with a high risk of acute complications, as well as substantial chronic organ toxicity. Therefore, in most patients who require intensive care unit (ICU) support, clinical deterioration is caused by complex and multi-factorial problems. Several reports have shown that once the patients require ICU support, their prognosis is poor and efforts have been made to define prognostic parameters in order to avoid extended and inappropriate ICU treatment. [1] [2] [3] [4] [5] [6] [7] [8] These studies revealed that the predictive value of the standard ICU prognostic scores is limited in the post transplantation setting, and that standard scores tend to underestimate mortality. 3, 5, 9, 10 This may be explained by other contributing factors (eg presence of GVHD, bleeding, infection etc) that are not included in the standard scoring systems. In addition, some parameters included in standard scores may be influenced by the intensive pretreatment that HSCT patients receive. For example, alterations in the coagulation system, blood gases and serum electrolytes may have been corrected prior to referral to ICU, and as a result a score that had been developed on standard patients will underestimate the risk of mortality.
This study was undertaken in order to determine variables of prognostic significance that may allow a feasible and reproducible evaluation of HSCT patients. For this purpose we analyzed 180 HSCT patients treated in the Düssel-dorf pediatric stem cell transplantation center, among whom 28 patients required ICU support. Established pediatric prognostic scoring systems such as the Pediatric Risk of Mortality (PRISM) score were applied. 11 In order to further enhance its prognostic impact, we added prognostically relevant HSCT-related parameters, such as severity of GVHD, CRP levels and presence of macroscopic bleeding to the PRISM score and thereby introduce a new oncological PRISM score ('O-PRISM').
Bone Marrow Transplantation

Patients and methods
Patients
Between January 1989 and December 1998, 180 patients underwent HSCT at the Düsseldorf pediatric stem cell transplantation center. All parents gave informed consent to analysis of the medical data prior to the start of the HSCT treatment.
The patients' characteristics including the demographic data, underlying disease and the HSCT-related parameters are listed in Table 1 . Conditioning regimens varied according to disease and type of transplant. In the allogeneic setting (related HSCT: 70 patients; unrelated HSCT: 42 patients), patients received anti-thymocyte-globulin, cyclo- Male  111  16  Female  69  12  Diagnosis  ALL/NHL  1st remission  8  -2nd remission  25  8  active disease  9  -AML/MDS  1st remission  14  1  2nd remission  4  1  active disease  16  2  CML  chronic phase  7  1  acc phase/blast crisis  2  -SAA  7  2  Neuroblastoma  stage IV  9  1  relapse  3  1  Ewing's sarcoma  stage IV  16  1  relapse  23  1  Multifocal sarcoma  12  2  Others  25  7  Donor  Autologous  68  5  Allogeneic-related  70  13  Unrelated  42  10  Type of transplant  Bone marrow  96  20  Periph blood stem cells  76  8  Cord blood  8  0  Total body irradiation  95  16  HLA-match (A, B, DR)  HLA-identical  87  16  HLA-mismatch  25  7  Acute GVHD  (allogeneic HSCT)  No  30  3  Grade 1-2  57  17  Grade 3-4  25  3  Status (October 1999)  Alive  80  6  Death of disease  58  3  Death of complication  42  19 phosphamide and either total body irradiation (12 Gy) or busulfan. GVHD prophylaxis was performed with methotrexate and cyclosporin A (at serum levels of 200-300 ng/ml following related and 300-400 ng/ml following unrelated HSCT). In patients receiving unrelated transplants and in HLA-mismatch situations an anti-CD25 antibody was given as described previously. 12 Conditioning therapy for autologous HSCT usually consisted of melphalan and etoposide (in some patients plus carboplatinum) combined with total body irradiation. 13, 14 Some patients received two consecutive autologous transplants following conditioning therapy with melphalan and etoposide without additional total body irradiation.
14 Twenty-eight patients were admitted to the ICU during the first year after HSCT. Patients admitted to the ICU more than 1 year after HSCT, and patients referred to the ICU for post-surgical management were excluded from analysis.
Clinical and laboratory parameters
The complete medical records that included transplantationrelated data, conditioning regimen and HSCT complications were evaluated. The clinical data at the time of admission to ICU were analyzed, ie heart and respiration rate, blood pressure, oxygen saturation, laboratory values (blood gases, blood count, CRP, bilirubin, creatinine, urea, coagulation profiles), the microbiological and the virological findings. The initial therapeutic measures such as hemodynamic and ventilator support or hemodialysis/ hemofiltration, as well as further treatment intensification in the ICU were recorded in detail.
Based on these data different scoring systems were retrospectively calculated. The Pediatric Risk of Mortality Score (PRISM) 11 is based on 14 central physiologic parameters to be evaluated during the first hours after admission to the ICU ( Table 2 ). The Prehospital Therapeutic Intervention Score (P-TISS) includes 73 items and describes the intensity of treatment before referral to the ICU, 15 whereas the Therapeutic Intervention Score (TISS, 73 items) is a parameter of treatment intensity in the ICU. 16 The higher the scores, the more care provided to the patient. The latter scores were applied as parameters of cumulative therapeutic intensity in order to avoid a treatment bias in distinct subgroups of patients. In 24 of 28 patients the complete clinical and laboratory data for the calculation of the PRISM, P-TISS and TISS scores were available.
Endpoints
Success of ICU treatment was defined as discharge from the ICU to the HSCT unit. Death in the ICU was declared as failure of ICU treatment. In case of discharge from the ICU the medical records were analyzed for long-term complications of HSCT or ICU treatment. At the time of this report the minimum follow-up for the survivors was more than 2 years.
Definition of the O-PRISM score
The O-PRISM score was calculated on the basis of the standard PRISM score plus additional points according to the severity of GVHD (autologous HSCT or GVHD grade 0-1, 0 points; grade 2, 2 points; grade у3, 4 points.), CRP levels (CRP Ͻ10 mg/dl, 0 points; CRP у10 mg/dl, 4 points) and macroscopic bleeding (none, 0 points; present, 4 points) ( Table 2 ). The data were analyzed using contingency tables. Categorical data were calculated with the Pearson 2 test and continuous numeric data were analyzed with the MannWhitney U test. Parameters that influenced survival after discharge from the ICU were analyzed separately. A stepwise logistic regression analysis was conducted to determine independent prognostic variables. Parameters with a probability below 0.05 were entered, and parameters with a probability higher than 0.1 were excluded from the regression analysis. All tests were two-sided. P values below 0.05 were regarded as significant.
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Results
Referral to ICU
Most patients that required ICU support (n ϭ 28) received an allogeneic HSCT for treatment of hematological neoplasms (lymphoma or ALL in у2nd remission (n ϭ 8) or myelogenous leukemia (n ϭ 5), Table 1 ). Five of six patients with solid tumors received autologous transplants, and one patient with a multifocal Ewing's sarcoma underwent an (HLA-identical) allogeneic-related HSCT. The other diagnoses were severe aplastic anemia, familial hemophagocytic lymphohistiocytosis (each n ϭ 2), severe combined immunodeficiency, adrenoleukodystrophy, Wiskott-Aldrich syndrome, Fanconi anemia and congenital erythropoietic porphyria (each n ϭ 1); these patients received allogeneic-related (n ϭ 4) or unrelated (n ϭ 5) transplants.
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The median time of referral to the ICU was 61 (4 to 282) days after HSCT. Twenty-five of 28 patients were referred after leukocyte engraftment, and only three patients were referred during marrow aplasia. Ten of 28 patients were independent of thrombocyte transfusions, and seven of 28 patients were independent of erythrocyte transfusions.
Immunological data
The demand for ICU support was significantly higher among patients that had previously received an allogeneic HSCT (Table 1) . In all patients receiving allogeneic transplants the match of at least the HLA-A, -B and -DR locus had been determined before HSCT. Eighty-seven of 112 allogeneic transplanted patients received an HLA-identical transplant. Sixteen of 87 matched HSCT patients and seven of 25 mismatched patients were referred to the ICU (not significant). Neither the type of donor in the allogeneic setting, the type of transplant (bone marrow vs blood stem cells) nor the conditioning treatment (inclusion of TBI) significantly influenced the referral rate to the ICU. In three of 23 patients receiving allogeneic HSCT, a severe GVHD of grade 3 (according to the Seattle classification) was observed at the time of referral to the ICU.
Documented infections at admission to ICU
Two patients had positive blood cultures (Listeria greyi, one patient; coagulase-negative Staphylococcus, one patient). In six patients with severe pneumonia, bacterial (n ϭ 2), fungal (n ϭ 2) or viral (n ϭ 2) pathogens were identified. In 13 patients with ventilator-dependent respiratory failure, no pulmonary pathogens were detected. These patients were diagnosed as adult respiratory distress syndrome. We observed four patients with a polyomavirusassociated hemorrhagic urocystitis. In general, there was a trend toward a higher prevalence of viral infections (Table  3) following unrelated HSCT (6/10 patients) vs related HSCT (4/13 patients) or autologous HSCT (1/5 patients).
Organ support at admission to ICU
Eight patients were treated with hemodialysis/ hemofiltration, or they were referred for this purpose in a (Table 4) . Nine patients suffered from cardiovascular collapse, and six patients required cardiopulmonary resuscitation prior to admission. Two of nine patients with cardiovascular failure were stabilized by volume replacement therapy only, whereas seven patients required additional vasopressor support at admission. Three patients were referred to the ICU because of refractory epileptic seizures. Two patients required mechanical ventilation for their epileptic state. All patients referred to the ICU for epileptic seizures were discharged from the ICU. Taken together, three patients showed no evidence of organ failure, 15 patients had one-organ failure, five patients twoorgan failure and five patients three-organ failure respectively (Table 5 ).
Outcome
Fourteen of 28 patients (50%) were discharged from the ICU to the HSCT unit. Six of 28 patients (21%) achieved a long-term survival (median: 241 (122 to 408) weeks). For those patients that required mechanical ventilation the ICU discharge rate was 36% and the long-term survival rate was 14%. The survival rate after discharge from the ICU was 43% (6/14 patients). The long-term survivors have been followed-up for more than at least 2 years at the time of this report. The Lansky/Karnovsky score in all of these patients is higher than 80 and they report a sufficient subjective quality of life. Table 6 summarizes the impact of the type of transplant on outcome of the patients treated in the ICU. Although patients admitted to the ICU after unrelated HSCT did not have a worse short-term prognosis compared to others, the long-term survival of this group was impaired mostly as a result of additional supervening complications such as infection and exacerbation of GVHD during the post-ICU follow-up. Severe acute GVHD contributed to the acute clinical deterioration that led to the ICU referral only in a minority of patients. All patients with GVHD of grade Ͼ2 died (on ICU, one patient; after discharge from ICU, two patients), and as a result the HSCT parameters such as type of transplant and presence of severe GVHD у grade 3 Twelve patients had one indication for admission to ICU, 11 had two indications, and five had three indications, respectively. Definitions: respiratory failure, need of mechanical ventilation; shock, vasopressor support (infusion of dopamine at a rate higher than 5 g/kg/min, epinephrine, norepinephrine); renal failure, need of hemodialysis or hemofiltration; no organ failure, none of the above. inversely correlated with the probability of long-term survival (P ϭ 0.002). The short-term survival, defined as discharge from the ICU to the HSCT unit, correlated with cardiovascular status (first mean arterial blood pressure (MAP) at admission or need of vasopressor support, Table 7 ). In addition, clinical signs of macroscopic bleeding from the mucosae (P ϭ 0.03) and abundant CRP levels (P ϭ 0.02) were associated with fatal outcome (Figure 1) . The logistic regression analysis defined high CRP levels (P ϭ 0.04), cardiovascular instability (P ϭ 0.04) and presence of macroscopic bleeding (P ϭ 0.04) as parameters that were associated with an unfavorable short-term prognosis.
Prognostic parameters
The respiratory, cardiovascular and renal status at admission, measured as demand of replacement for or support of organ function ( Table 6 ), revealed that multi-organ failure Table 7 Prognostic factors at admission to ICU was associated with a fatal outcome. No patient survived multi-organ failure. In addition, the development of cardiovascular instability in mechanically ventilated patients was associated with impaired outcome. Renal failure was associated with poor long-term survival.
Introduction of a modified Pediatric Risk of Mortality scoring system
The evaluation of the P-TISS score revealed that patients that later died in the ICU received a slightly more intensive pretreatment on the HSCT unit (P-TISS, death on ICU vs discharge from ICU, median score, 31 (range, 21-53) vs 30 (18-40), P ϭ 0.14). Patients that died on the ICU were significantly more intensively treated on the ICU than patients that were discharged from the ICU (TISS, 47 (38- Death on ICU Discharge from ICU Outcome Figure 1 Comparison between median CRP levels (and 95% confidence interval) in patients that survived ICU and patients that died on ICU (P ϭ 0.02).
66) vs 37 (15-48), P ϭ 0.03). Therefore, under-treatment as a significant cause of mortality could be excluded. In our cohort the PRISM score did not reach statistical significance (PRISM, 16 (6-38) vs 11 (0-30), P ϭ 0.07). This was mainly due to the large range of overlaps between the survivor and non-survivor groups (Figure 2 ). To further enhance the predictive strength of the PRISM score, we included prognostically relevant HSCT-related parameters (severity of GVHD, CRP levels, macroscopic bleeding) into the oncological PRISM score ('O-PRISM', Table 2 ). The O-PRISM scores were significantly higher in patients who died on the ICU (median, 23 (range, 14-46)) compared to patients who were discharged from the ICU (15 (0-33); P ϭ 0.01). The O-PRISM score better distinguished between both prognostic groups than the PRISM score ( Figure 2 ). Patients with scores higher than 20 points were at a higher risk of death on ICU (odds ratio: 2.5 (95% confidence interval: 1.1-5.8). Since patients receiving auto- logous transplants are not at risk of GVHD, the O-PRISM scores were lower than in the allogeneic setting (15 (6-35) vs 20 (0-46)).
Discussion
ICU treatment of children after HSCT presents extreme challenges for both the treating physicians and the child with its caring family. Therefore, prognostic factors have been studied in these patients in order to appropriately define therapeutic goals of ICU treatment in this specific clinical setting and to avoid inappropriate life support. These mostly retrospective studies have reported significantly varying results for both referral rates to the ICU and survival rates. [2] [3] [4] [5] [6] [7] [8] 10 In general, studies that report a high demand of ICU support tend to report a more favorable outcome of ICU treatment following HSCT. It can be assumed that specific referral strategies rather than significant differences in the quality of ICU support may account for these discrepancies, as a restricted use of ICU referrals will select only the most compromised patients, thus resulting in an inferior outcome compared to other studies with higher ICU referral rates. In addition, it has to be considered that in some studies patients referred to the ICU after standard surgical procedures have been included, which could result in an overestimation of the overall survival rates. 2, 7 Different HSCT cohorts may also account for divergent referral and survival rates because allogeneic and unrelated HSCT are associated with a higher demand for ICU support (Table 1 ). In addition, we observed a high proportion of patients in у2nd remission of the underlying disease, and probably the higher amount of pretreatment and treatmentrelated organ toxicity may further contribute to the substantial risk of these patients. Therefore, the proportion of HSCT patients referred to the ICU, the indications of ICU referral and the HSCT-related parameters must be evaluated before prognostic parameters may be compared between different studies.
Referral rate, time of referral and indications for intensive care
Compared to one study that reported a high incidence of ICU support in the early phase after HSCT, 3 we and others observed the highest risk later in the course of HSCT treatment. 2, 17 This suggests that we successfully treated the typical acute HSCT-related complications during marrow aplasia such as sepsis, veno-occlusive disease of the liver 18 and capillary leakage syndrome. 19 These observations illustrate the success of modern antibiotic regimens that help to treat bacterial infections during marrow aplasia. On the other hand, with the duration of immunosuppression and antibiotic treatment, a selection towards resistant pathogens occurs (Table 3 and Ref. 2). This may account for lifethreatening infections in the later course of HSCT treatment. Furthermore, additional immunological parameters such as the donor T cell repertoire or delayed T and B cell reconstitution may contribute to the risk of severe infections in the later course of HSCT treatment. The prognostic impact of uncontrolled infections is reflected by abundant CRP levels which significantly correlate with an unfavorable outcome (Figure 1) .
Our data confirm previous reports that the need for mechanical ventilation represents the most frequent cause for referral to the ICU (Table 4) . 2, 3, 20, 21 This finding may be explained by the broad therapeutic repertoire of most HSCT units. In the Düsseldorf HSCT unit, treatment includes organ replacement therapy such as hemodialysis/ hemofiltration, hemodynamic support with one or more vasopressors and volume replacement therapy, as well as the treatment of capillary leakage syndrome with complement inhibitors. 19 Only mechanical ventilation is not provided by our unit and most other HSCT units. Therefore, most HSCT patients are not referred to the ICU until ventilator-dependent respiratory failure occurs in order to minimize the risk of exogenous infections.
In most patients respiratory failure is due to either pneumonia or adult respiratory distress syndrome. 2, 3, 6, 7, 17, 20, 21 We observed a high frequency of pulmonary and non-pulmonary infections. Pneumonia was clinically suspected in the majority of the patients who required mechanical ventilation. Significant pulmonary pathogens could be isolated in only six patients. This may be due to the previous broad antibiotic pretreatment (at admission our patients received a median of three antibiotics) which adversely influences the microbiological assessment. Therefore, it will remain impossible in some patients to clearly delineate between ARDS and pneumonia or pneumonitis.
Outcome of ICU patients and prognostic variables for discharge from ICU
According to the current literature on HSCT patients needing ICU support, the survival rates may vary between 12% and 33%, partly depending on the cohort (eg inclusion of post-surgical patients). 3, 6, 20, 21 The survival rates of ventilator-dependent patients varied from 4% to 17%. 3, 6, 7, 20, 22 In general, our results are comparable to these data, even with our referral rate to ICU (15.5%) being considerably lower compared to other studies that reported referral rates between 16% and 40%. 2, 3, 17, [20] [21] [22] [23] In our cohort the HSCT-related parameters such as type of transplant and conditioning therapy did not significantly influence the success of ICU treatment. Death in the ICU correlated with the parameters that characterized the acute clinical deterioration such as circulatory instability, infection and macroscopic bleeding (Table 7) . It may be true that these factors all reflect the same clinical situation (eg septic shock). Nevertheless, the logistic regression analysis revealed that the appearance of each of these parameters seemed to further indicate a more unfavorable outcome.
The occurrence of multiple organ failure was associated with a significantly impaired prognosis. In our study, organ failure was defined by the demand of supportive therapy or organ-replacement therapy of the cardiovascular, respiratory or renal systems. This approach has previously been used by others, 3 and our study supports the reported data that the intensity of treatment allows definition of subgroups of prognostic significance (Table 5) . 3 However, this approach represents only a very rough estimate, and more Bone Marrow Transplantation elaborate prognostic scoring systems are required to allow for a more accurate prediction of the outcome.
Introduction of the O-PRISM score
The main objective of this study was to determine variables of prognostic significance that may allow a feasible and reproducible evaluation of HSCT patients. For this purpose prognostic scoring systems based on physiological parameters help to compare different cohorts of patients. However, it must be considered that they do not unequivocally predict outcome in an individual patient due to their large confidence intervals. 10, 11, 24 Prognostic scores must include the most essential physiological variables which should be reproducible and easy to obtain. It should be taken into account that a narrow design of the scores, that includes only a few variables, may exclude relevant parameters from the analysis. Therefore, it seems justifiable to adapt standard scoring systems to specific clinical situations by including additional parameters rather than excluding parameters. This approach helps to combine the advantages of prospectively evaluated scoring systems with prognostically relevant parameters which are related to a specific clinical setting and which can be evaluated in a limited number of patients only.
The post-HSCT situation is characterized by a high rate of potentially life-threatening complications and sustained treatment toxicity. Our retrospective data show that the standard PRISM score does not appropriately characterize the clinical situation of children that require ICU support after HSCT. This finding is in accordance with other studies which also report that standard scoring systems tend to substantially underestimate the risk of mortality. 3, 5, 9, 10 Since its introduction in 1988, the PRISM score has been updated repeatedly (1996: PRISM III) and, among other changes, new variables such as creatinine, thrombocytes and blood urea nitrogen have been added to the score. 25 These variables were not prognostically significant in our cohort and, as a result, the updated PRISM III score did not achieve a higher level of prognostic significance than the PRISM score. Therefore, we used the simpler PRISM score as a template for the new, HSCT-specific O-PRISM score.
In order to enhance the prognostic value of the standard PRISM score, we added those HSCT-related variables to the score that correlated with the outcome of our patients (Tables 2 and 7) .
In analogy to the general scoring strategy of the PRISM score (Table 2 ) and in the light of the logistic regression analysis, we chose a maximum of four points for each variable. We distinguished between CRP levels below or above 10 mg/dl, as this value appeared to be the most appropriate cut-off value (Figure 1 ). In the evaluation of the severity of GVHD we distinguished between patients with involvement of internal organs (eg liver, intestine: grade 2: 2 points) and severe, life-threatening GVHD (grade Ͼ2: 4 points). Figure 2 illustrates that these changes resulted in a better discrimination between success and failure of ICU treatment following HSCT compared to the standard PRISM score.
As this score includes variables that are usually obtained during standard ICU care, it can be easily calculated. Thus, the O-PRISM score may be feasible for the routine evaluation of HSCT patients in the ICU both at admission and on repeated assessments. Large scale, prospective studies may then address the issue of whether in prognostically fatal situations, withdrawal of extended ICU treatment and life-support might be justified. These studies may also help to define conditions for clinical trials on improved therapeutic strategies in children requiring ICU support.
